What Is Fibroblast Growth Factor 2? Definition and What Research Reports
Fibroblast growth factor 2 (FGF2), also written FGF-2 or basic fibroblast growth factor, is a heparin-binding signalling protein in the fibroblast growth factor family, produced by many cell types and stored in the extracellular matrix. In peptide and protein research it is used as a laboratory growth factor and as a signalling target. Published studies have examined FGF2 in mineralised tissue, fibroblast activation, muscle and gait in knockout mice, tumour biology, kidney disease models, and engineered protein variants.
Plain-language definition
Fibroblast growth factor 2 (FGF2) — also written FGF-2 and historically called basic fibroblast growth factor (bFGF) — is a small, heparin-binding signalling protein belonging to the fibroblast growth factor (FGF) family. It is produced by many cell types, including fibroblasts, endothelial cells and cells of bone and nervous tissue, and a substantial fraction of it is held in the extracellular matrix bound to heparan sulfate rather than circulating freely. FGF2 acts by binding FGF receptors on the cell surface, which in turn influences processes such as cell proliferation, migration and differentiation. Two dedicated review articles published in The International Journal of Biochemistry & Cell Biology in 2000 surveyed the structure and biology of FGF2 (PMID 10687947, PMID 10716624), and a more recent overview of FGF2 appeared in Differentiation in 2024 (PMID 37858405).
This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, treatment or the use of any substance. Nothing here describes how FGF2 should be used, and the entry is definitional rather than instructional.
What class of molecule is it?
FGF2 is a protein growth factor, not a short synthetic peptide. It is encoded by the FGF2 gene and is translated into several forms. A low-molecular-weight (LMW) form is the one most often used in cell culture, while alternative translation start sites also generate high-molecular-weight (HMW) isoforms that carry nuclear localisation signals and can act inside the cell rather than through surface receptors. Researchers examining dentoalveolar mineralisation specifically studied FGF2 HMW isoforms and reported on their role in mineralised tissue formation (PMID 34245331), illustrating that the different isoforms are treated as biologically distinct entities in the literature.
Where it comes from
Endogenously, FGF2 is made by the body's own cells and stored in the extracellular matrix and basement membranes. For laboratory work, FGF2 is typically produced as a recombinant protein in bacterial or mammalian expression systems. Because native FGF2 is relatively unstable in solution, protein engineers have built modified versions: a 2022 study in the International Journal of Biological Macromolecules described cyclic and dimeric FGF2 variants and characterised them as having high biomedical potential (PMID 35878661), and a 2022 Journal of Controlled Release study reported an affibody-based system for controlled release of FGF2 (PMID 36087800).
How the term is used in peptide and protein research
In research contexts, "FGF2" is used in several different ways, and the meaning depends on the setting:
- As a laboratory reagent. Recombinant FGF2 is a standard supplement in stem-cell and primary-cell culture media, used to keep cells proliferating or undifferentiated.
- As an endogenous signal. Papers refer to FGF2 as a molecule the body produces, measuring its levels in tissue, serum or plasma and correlating those levels with a biological state.
- As a delivery or engineering problem. Because the protein is short-lived, work focuses on stabilised variants and controlled-release systems, as in the affibody-mediated release study (PMID 36087800) and the cyclic and dimeric variant study (PMID 35878661).
- As a target. Some investigations aim to block FGF2 signalling rather than supply it; a 2022 computational investigation in Frontiers in Chemistry reported FGF2 to be a druggable target against glioblastoma (PMID 36505741).
FGF2 is a research protein and a laboratory reagent; it is not an over-the-counter consumer product, and the published work summarised below is largely preclinical — cell culture, mouse models and computational analysis — plus observational human measurements.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeWhat the published literature reports
Mineralised tissue and periodontal biology
Researchers investigating dentoalveolar mineralisation reported on FGF2 high-molecular-weight isoforms in that setting, examining how the nuclear isoforms relate to mineralised tissue formation (PMID 34245331). In a separate line of work, a 2019 study in the Journal of Cellular Physiology reported that FGF2 inhibited CD40-mediated periodontal inflammation (PMID 30370560), placing FGF2 in an anti-inflammatory role within that specific signalling pathway.
Fibroblast activation and fibrosis
Although FGF2 was named for its mitogenic effect on fibroblasts, a 2023 FEBS Open Bio study reported that FGF2 acted as an upstream regulator of the inhibition of pulmonary fibroblast activation (PMID 37583315). That the same molecule can both drive proliferation and restrain activation depending on cell type and context is a recurring theme in the FGF2 literature and is one reason the 2000 reviews and the 2024 overview treat FGF2 as a highly context-dependent signal (PMID 10687947, PMID 37858405).
Muscle, gait and the nervous system
A 2021 Scientific Reports study used fibroblast growth factor 2 knockout mice and reported gait disturbances and muscle dysfunction in animals lacking the protein (PMID 34040128), a loss-of-function observation rather than a supplementation experiment. On the human side, a 2021 paper in the Journal of Affective Disorders reported that FGF2 was implicated in childhood anxiety and depression symptoms (PMID 33445083); that work is associative and does not establish that changing FGF2 changes symptoms.
Disease models where FGF2 was unfavourable
Not every finding points in a beneficial direction. A 2021 study in Disease Models & Mechanisms reported that circulating fibroblast growth factor-2 precipitated HIV nephropathy in mice (PMID 34308967), and the computational glioblastoma work framed FGF2 as something to be inhibited rather than supplied (PMID 36505741). Readers encountering FGF2 described only as a "regenerative" factor are seeing one side of a literature that also documents pathological roles.
Study snapshot
| Focus | Model | What researchers reported |
|---|---|---|
| HMW isoforms | Dentoalveolar tissue | FGF2 high-molecular-weight isoforms were examined in dentoalveolar mineralisation (PMID 34245331) |
| Inflammation | Periodontal cells | FGF2 inhibited CD40-mediated periodontal inflammation (PMID 30370560) |
| Fibrosis | Pulmonary fibroblasts | FGF2 acted as an upstream regulator of inhibition of pulmonary fibroblast activation (PMID 37583315) |
| Neuromuscular | Knockout mice | Gait disturbances and muscle dysfunction were reported in FGF2 knockout mice (PMID 34040128) |
| Mood symptoms | Human children | FGF2 was implicated in childhood anxiety and depression symptoms (PMID 33445083) |
| Kidney | Mice | Circulating FGF2 precipitated HIV nephropathy (PMID 34308967) |
| Oncology target | Computational | FGF2 was described as a druggable target against glioblastoma (PMID 36505741) |
| Protein engineering | In vitro | Cyclic and dimeric FGF2 variants were characterised (PMID 35878661); affibody-mediated controlled release of FGF2 was reported (PMID 36087800) |
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appSafety and Adverse Events: What Studies Report
The verified literature collected here is mostly preclinical and does not contain human dosing trials of administered FGF2, so no dose figures are stated on this page. The clearest adverse finding in these papers came from a mouse model in which circulating FGF2 precipitated HIV nephropathy, an outcome researchers reported as harmful rather than protective (PMID 34308967). The glioblastoma analysis likewise treated FGF2 signalling as a target for inhibition (PMID 36505741). Animal and computational findings do not transfer directly to people, and the study designs summarised above were not built to characterise human safety.
Related terms
- bFGF / basic FGF — older names for the same protein.
- FGF family — the broader group of related growth factors described in reviews of FGF2 biology (PMID 10716624).
- HMW and LMW isoforms — translation variants, with the high-molecular-weight forms studied in mineralisation research (PMID 34245331).
- Affibody — an engineered binding scaffold used in an FGF2 controlled-release system (PMID 36087800).
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeReferences
- Fibroblast growth factor-2 (The International Journal of Biochemistry & Cell Biology, 2000)
- Fibroblast growth factor-2 (The International Journal of Biochemistry & Cell Biology, 2000)
- Fibroblast growth factor 2 (Differentiation, 2024)
- Affibody-mediated controlled release of fibroblast growth factor 2 (Journal of Controlled Release, 2022)
- Fibroblast Growth Factor 2 High Molecular Weight Isoforms in Dentoalveolar Mineralization (Calcified Tissue International, 2022)
- Fibroblast growth factor-2 inhibits CD40-mediated periodontal inflammation (Journal of Cellular Physiology, 2019)
- Fibroblast growth factor 2 acts as an upstream regulator of inhibition of pulmonary fibroblast activation (FEBS Open Bio, 2023)
- Gait disturbances and muscle dysfunction in fibroblast growth factor 2 knockout mice (Scientific Reports, 2021)
- Fibroblast growth factor 2 is a druggable target against glioblastoma: A computational investigation (Frontiers in Chemistry, 2022)
- Fibroblast Growth Factor 2 Implicated in Childhood Anxiety and Depression Symptoms (Journal of Affective Disorders, 2021)
- Circulating fibroblast growth factor-2 precipitates HIV nephropathy in mice (Disease Models & Mechanisms, 2021)
- Cyclic and dimeric fibroblast growth factor 2 variants with high biomedical potential (International Journal of Biological Macromolecules, 2022)
Frequently asked questions
Is FGF2 a peptide or a protein?▾
FGF2 is a protein growth factor rather than a short synthetic peptide, and it is encoded by the FGF2 gene. Review articles on FGF2 surveyed its structure and family membership (PMID 10687947, PMID 10716624), and a 2024 overview revisited its biology (PMID 37858405). Laboratory material is typically recombinant, produced in expression systems rather than by solid-phase peptide synthesis.
What does basic FGF (bFGF) mean?▾
"Basic FGF" and "bFGF" are older names for the same molecule now standardised as fibroblast growth factor 2. The name distinguished it from acidic FGF, later renamed FGF1. Reviews published under the title "Fibroblast growth factor-2" summarised the protein's biology under this nomenclature (PMID 10687947, PMID 10716624), and newer papers use FGF2 or FGF-2 interchangeably (PMID 37858405).
What are FGF2 high-molecular-weight isoforms?▾
The FGF2 gene produces more than one protein form. Alongside the low-molecular-weight form used in cell culture, high-molecular-weight (HMW) isoforms carry nuclear localisation signals and can act inside cells. Researchers examined FGF2 HMW isoforms specifically in dentoalveolar mineralisation and reported on their role in mineralised tissue (PMID 34245331), showing that isoforms are treated as distinct in the literature.
What have animal studies of FGF2 reported?▾
A 2021 knockout study reported gait disturbances and muscle dysfunction in mice lacking fibroblast growth factor 2 (PMID 34040128). A separate mouse study reported that circulating FGF2 precipitated HIV nephropathy (PMID 34308967). These are loss-of-function and disease-model observations in rodents; they describe FGF2 biology rather than establishing outcomes in humans.
Why do some studies try to block FGF2 instead of supplying it?▾
Because FGF2 signalling can support tumour biology. A 2022 computational investigation reported FGF2 to be a druggable target against glioblastoma, framing inhibition as the goal (PMID 36505741). A mouse study also reported that circulating FGF2 precipitated HIV nephropathy (PMID 34308967). The literature therefore describes both regenerative and pathological roles depending on tissue and context.
Why is FGF2 studied with delivery systems and engineered variants?▾
Native FGF2 is unstable in solution, which limits its usefulness in experimental systems. Researchers reported an affibody-mediated approach for controlled release of fibroblast growth factor 2 (PMID 36087800), and a separate group described cyclic and dimeric FGF2 variants characterised as having high biomedical potential (PMID 35878661). Both lines of work address stability and release rather than clinical administration.
Does FGF2 promote or suppress fibroblast activation?▾
It depends on context. Despite its name, a 2023 study reported that FGF2 acted as an upstream regulator of the inhibition of pulmonary fibroblast activation (PMID 37583315). A separate study reported that FGF2 inhibited CD40-mediated periodontal inflammation (PMID 30370560). Reviews of FGF2 biology describe it as a highly context-dependent signal whose effects vary by cell type (PMID 10687947, PMID 37858405).
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.